As the stock market rotates away from mega-cap tech, three undervalued stocks offer compelling opportunities: Keurig Dr Pepper trades at a discount to beverage peers with attractive dividend yield; Cooper Companies benefits from healthcare sector resilience with strong EPS growth prospects; and Matador Resources capitalizes on the energy sector's 21% YTD surge with robust revenue growth and cash flow metrics.

The global ART market is projected to grow from $30.1 billion in 2024 to $60.7 billion by 2033 at a CAGR of 8.1%, driven by rising infertility prevalence, delayed parenthood, and expanding employer-sponsored fertility benefits. IVF dominates with 90% market share, while Europe leads with 35.80% of the global market. Over 450 Fortune 500 companies now offer fertility benefits, with specialized platforms facilitating over 500,000 virtual consultations in 2024.

The global ART market is projected to grow from $30.1 billion in 2024 to $60.7 billion by 2033 at a CAGR of 8.1%, driven by rising infertility prevalence, delayed parenthood, and expanding employer-sponsored fertility benefits. IVF dominates with 90% market share, while Europe leads with 35.80% of the global market. Over 450 Fortune 500 companies now offer fertility benefits, with specialized platforms facilitating over 500,000 virtual consultations in 2024.

The global contact lens market is projected to grow from USD 18.88 billion in 2025 to USD 26.64 billion by 2033, expanding at a CAGR of 4.42%. Growth is driven by rising myopia prevalence, increasing adoption of disposable lenses, and technological advancements in silicone hydrogel materials. However, risks from eye infections and user discomfort may hinder expansion. The U.S. market leads North America with expected growth to USD 6.83 billion by 2033.

A Georgia federal judge denied Teva Pharmaceutical's request to delay the first trial in approximately 3,800 lawsuits alleging its Paragard copper IUD can fracture during removal. The trial is scheduled to proceed on January 20. The judge previously expressed concerns about Teva's five-year delay in complying with an FDA mandate to update warning labels and rejected the company's preemption defense arguments.

CooperCompanies announced the appointment of Walt M Rosebrough, Jr., former CEO of STERIS, as an independent director effective January 3, 2026, following a cooperation agreement with activist investor Browning West. Rosebrough will join the Corporate Governance & Nominating Committee with consideration for Board Chair by end of 2026. The company also committed to appointing a new independent director with medical technology experience.

Cooper Companies reported strong Q4 earnings, beating expectations, and announced a portfolio review to unlock long-term value. The company expects positive organic growth and raised fiscal 2026 guidance.

U.S. stock futures recovered early losses ahead of the Federal Reserve's PCE inflation data. Netflix announced an $82.7 billion deal to acquire Warner Bros Discovery, while job cuts fell 53% month-over-month in November. Markets anticipate potential interest rate cuts in December.

Browning West, a major shareholder, criticized Cooper Companies for underperformance, weak governance, and misaligned capital allocation strategies across its CooperVision and CooperSurgical divisions.

Alcon reported Q3 sales of $2.59 billion, slightly missing consensus but beating earnings expectations. The company saw strong growth in surgical and vision care segments, with promising new technologies like Unity VCS and PanOptix Pro.

Activist investor Jana Partners has taken a stake in Cooper Companies and is pushing for strategic alternatives, including a potential merger between Cooper's contact lens division and Bausch + Lomb to improve shareholder value.

Cooper Companies reported Q3 fiscal 2025 revenue of $1.06 billion, slightly meeting analyst estimates but falling short of internal expectations. Despite a 6% revenue increase and 15% growth in adjusted net income, the stock dropped 13% due to lower-than-anticipated organic growth.